Harnessing Disruptive CAR & TCR Based Cell Technologies to Supercharge Safe, Effective & Globally Accessible Cell Immunotherapies in Oncology & Beyond.
The 6th Annual CAR-TCR Summit returns in 2021 as the industry-leading comprehensive forum with one goal: to engineer a disease-free world.
August 30-September 2, 2021 | Digital - EDT
October 24, 2022
Video
The senior vice president of Research & Early Development at Notch Therapeutics discussed the company’s approach to overcoming the drawbacks of autologous cell therapies.
October 10, 2022
Video
The chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.
October 08, 2022
Video
The senior scientist at Thermo Fisher Scientific discussed the company’s approach to scaling and strategic partnerships.
September 29, 2022
Video
The senior vice president of Technical Operations at Senti Biosciences discussed the company’s NK cell logic-gating platform and allogeneic approach.
September 28, 2022
Video
Phil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.
September 22, 2022
Article
Interim data showed a 78% overall response rate and a 67% complete response rate.
September 22, 2022
Article
Eleven patients in the LUMMICAR-2 trial were evaluable for preliminary efficacy analyses.
September 01, 2021
Article
The early-phase data readout follows news that the FDA recently approved its IND for its CAR-T candidate in multiple myeloma.
August 27, 2021
Article
The 4-day virtual conference will feature plenary presentations, workshops, and bootcamps led by cell therapy industry leaders with expertise in discovery, development, manufacturing, and more.